louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05458206: Effect of Mulligan Snag and Diaphragmatic Release on Thoracic Kyphosis
Official title: Effect of Mulligan Snag and Diaphragmatic Release on Thoracic Kyphosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postural Kyphosis, Cervicothoracic Region
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-07-14
Enrollment: 60
Sex: ALL
Minimum age (years): 17
Maximum age (years): 22
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: EFFECT OF MULLIGAN SNAG MOBILISATION AND DIAPHRAGMATIC RELEASE
Primary purpose: TREATMENT

Brief summary: the aim of this study is to investigate the efficacy of mulligan snag mobilisation and diaphragmatic release on upper crossed syndrome

Detailed description: Acquired postural disorders can be a consequence, to a large extent, of contemporary living and working conditions. Some of the most typical factors include continuous use of mobile phones and computers, working in sedentary jobs. Prolonged incorrect posture and reduced physical activity present a dis-balance in the musculature . It can also lead to vision issues, as well as headaches, musculoskeletal issues, and pain, as well as a multitude of other symptoms.

Upon the available research studies, there is not study conducted to investigate the effect of mulligan SNAG mobilization and diaphragmatic release in upper crossed syndrome patients this trial has four groups; one will receive diaphragmatic release + conventional, the second will receive mulligan SNAG mobilization, and conventional, the third will receive mulligan SNAG mobilization+diaphragmatic release+conventional, the fourth subjects will receive conventional

Eligibility criteria: Inclusion Criteria:

* Age ranged from 17 to 22 years .
* Body Mass Index from 20 to 25 kg/m² .
* All participants have an intensity of neck pain on VAS (4-8) (moderate cases) .
* The subjects were chosen from both sexes.
* All participants have kyphosis angle ≥42°
* All participants have mechanical neck pain and FHP (craniovertebral angle CVA \< 49) CVA of \< 49) .

Exclusion Criteria:

* Malignancy
* Fractures of the cervical spine
* Cervical radiculopathy or myelopathy
* Vascular syndromes such as vertebrobasilar insufficiency
* Rheumatoid arthritis
* Neck or upper back surgery
* Taking anticoagulants
* Local infection
* Whiplash injury

Primary outcomes:
measure: pain intensity
timeFrame: up to four weeks
Secondary outcomes:
measure: cervical range of motion
timeFrame: up to four weeks
Other outcomes:
measure: forward head
timeFrame: up to four weeks
measure: kyphotic angle
timeFrame: up to four weeks
measure: chest expansion
timeFrame: up to four weeks
Locations:
city: Cairo
country: Egypt
facility: Faculty of physical therapy Cairo university
state: Giza
city: Cairo
country: Egypt
facility: Faculty of physical therapy
state: Giza
Study officials:
References:
Clinical trial NCT05066906: Videogame-based Tool for Job Search and Executive Function Improvement in Adults With ASD
Official title: Assessing Videogame-Based Tool for Job Search and Executive Function Improvement in Adults With Autism Spectrum Disorder
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Autism Spectrum Disorder
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2021-10-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomization into two groups A and B. Group Intervention or group A will comprise of participants who will be given usual referrals to pre-employment training, and will not use Identifor or Companion app. Intervention or group B will comprise of participants who were randomly selected to use Identifor and Companion app, in addition to referrals to pre-employment training.
Primary purpose: DEVICE_FEASIBILITY

Brief summary: This study aims to assess the efficacy of Identifor, a strength- based, person-centered, vocational assessment tool to develop a more effective way to identify individual abilities, skills, and interests. Identifor uses computer games specifically designed for young adults with ASD.


Eligibility criteria: Inclusion Criteria:

* IQ above 60
* Diagnosis of ASD as confirmed by qualified clinician (including Dr. Fung), and if necessary the administration of Autism Diagnostic Interview-Revised (ADI-R) and/or Autism Diagnostic Observation Schedule-Generic (ADOS-G)
* Age 18 to 55
* Adults who are physically healthy
* able to travel to work independently

Exclusion Criteria:

* DSM-5 diagnosis of other severe psychiatric disorder such as schizophrenia

Primary outcomes:
measure: Rate of securing internship, part-time, or full-time positions
timeFrame: 6 months after initiation of referral
measure: Level of satisfaction
timeFrame: 3 months after initiation of referral
Secondary outcomes:
measure: Behavior Rating Inventory of Executive Function for Adults (BRIEF-A)
timeFrame: 6 months after initiation of referral
Other outcomes:
Locations:
Study officials:
affiliation: Stanford University
name: Lawrence Fung, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00656006: A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3
Official title: A Randomized, Multi-Center, Open-Label Study To Evaluate The Efficacy And Safety Of Albuferon (HGS 1008, Recombinant Human Albumin-Interferon Alfa Fusion Protein) In Combination With Ribavirin In Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 OR 3
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Hepatitis C
Keywords: Hepatitis C
Chronic
Genotype 2 or 3
Treatment naive
Lead sponsor: Human Genome Sciences Inc.
Sponsor class: INDUSTRY
First posted: 2008-04-10
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Study of Albuferon with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 2 or 3.

Detailed description: A Randomized, Multi-Center, Open-Label Study To Evaluate The Efficacy And Safety Of Albuferon (HGS 1008, Recombinant Human Albumin-Interferon Alfa Fusion Protein) In Combination With Ribavirin In Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 OR 3

Eligibility criteria: Inclusion Criteria:

* Have a clinical diagnosis of chronic hepatitis C on the basis of detectable serum HCV RNA during the screening period and at least a 6-month history of exposure to risk factors for HCV.
* Have never received treatment with an interferon alfa product or an interferon alfa combination product.
* Have HCV genotype 2 or 3.
* Have compensated liver disease with the following minimum criteria: white blood cell count (WBC) \>3,000/mm3, absolute neutrophil count (ANC) \> 1,800/mm3, platelets \>100,000/mm3, hemoglobin (Hb) \> 13 g/dL for males and \> 12 g/dL for females.

Exclusion Criteria:

* Evidence of decompensated liver disease.
* Pregnant or lactating female.
* History of any other medical disease or condition that would make the subject (in the opinion of the investigator) unsuitable for the study.
* A current drug or alcohol addiction.

Primary outcomes:
measure: Primary safety endpoints are the common side effects of IFNa therapy including flu-like symptoms, depression, and hematologic abnormalities.
measure: Primary efficacy end point is sustained virologic response (SVR), defined as undetectable HCV RNA at 24 weeks after the end of therapy.
Secondary outcomes:
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: University of Calgary
state: Alberta
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
city: Vancouver
country: Canada
facility: University of British Columbia
state: British Columbia
city: Winnipeg
country: Canada
facility: University of Manitoba
state: Manitoba
city: London
country: Canada
facility: University of Western Ontario
state: Ontario
city: Saskatoon
country: Canada
facility: University of Saskatchewan
state: Saskatchewan
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT00130806: An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)
Official title: A Study to Assess the Efficacy and Tolerability of MK0478 (Muraglitazar, Also, BMS 298585) Coadministered With Insulin in Patients With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
Collaborators: name: Bristol-Myers Squibb
First posted: 2005-08-16
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a study to evaluate the effectiveness and tolerability of an investigational drug in patients with type 2 diabetes (a specific type of diabetes) who are not currently treated with insulin.

Detailed description: The duration of treatment is 30 weeks.

Eligibility criteria: Inclusion Criteria:

* People between the ages of 18 and 70 who have a specific type of diabetes called type 2 diabetes which is currently being treated only with oral medication(s). (Patients currently taking insulin would not be allowed to participate.)

Exclusion Criteria:

* People who have specific diseases (such as liver disease, gallbladder disease, pancreatitis, severe blood disorders or history of neoplastic diseases) which will be discussed by the study doctor and for which study participation would not be allowed.

Primary outcomes:
measure: The difference in daily dose requirements of insulin after 24 weeks
Secondary outcomes:
measure: (a) HbA1C; (b) FPG; (c) Percent of patients with HbA1C <7.0%; (d) TG, HDL-C, non-HDL-C and apolipoprotein B; (e) Free Fatty Acids (FFA); (f) the incidence of hypoglycemic events at 24 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT00111306: Study of Epratuzumab in Systemic Lupus Erythematosus
Official title: A Phase III, Randomized, Double-Blind. Placebo-Controlled, Multi-Center Study of Systemic Lupus Erythematosus With Acute Severe SLE Flares Excluding Renal or Neurological Systems
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Systemic Lupus Erythematosus
Keywords: Lupus
Antibody
B-cell immunotherapy
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2005-05-20
Enrollment: 510
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the safety \& efficacy of Epratuzumab with standard treatments for patients with SLE.


Eligibility criteria: Inclusion Criteria:

* Has SLE by ACR revised criteria (meets \<4 criteria);
* Has SLE with at least one elevated lupus antibody;
* Has new onset of severe lupus disease flare in at least one body or organ system, excluding renal or neurologic

Exclusion Criteria:

* Active severe CNS or Renal disease defined by BILAG as Level A
* Allergy to murine or human antibodies
* Antiphospholid antibodies AND a history of thrombocytopenic events

Primary outcomes:
measure: Patient response variable (complete response, partial response, non-response) evaluated at 24 weeks.
Secondary outcomes:
measure: Proportion of patients with complete response or partial response;
measure: Individual BILAG assessments;
measure: Physician and patient assessment scores;
measure: Time-to treatment failure;
measure: Successful steroid reduction by weeks 20 and 24;
measure: Maintenance of steroid reduction at 24 and 48 weeks;
measure: Monitor the plasma concentration and immunogenicity profile of epratuzumab in patients with Lupus;
measure: Assess epratuzumab on Health-related quality of life.
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: Tucson
country: United States
state: Arizona
city: Los Angeles
country: United States
state: California
city: Upland
country: United States
state: California
city: Denver
country: United States
state: Colorado
city: Washington
country: United States
state: District of Columbia
city: Baltimore
country: United States
state: Maryland
city: Bronx
country: United States
state: New York
city: New York
country: United States
state: New York
city: Durham
country: United States
state: North Carolina
city: Winston-Salem
country: United States
state: North Carolina
city: Tulsa
country: United States
state: Oklahoma
city: Charleston
country: United States
state: South Carolina
city: Brussels
country: Belgium
city: Debrecen
country: Hungary
city: Amsterdam
country: Netherlands
city: Santander
country: Spain
city: Birmingham
country: United Kingdom
Study officials:
affiliation: UCB Pharma
name: Anna Barry
role: STUDY_DIRECTOR
References:
citation: Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2.
Clinical trial NCT01220206: POMx In the Treatment of Erectile Dysfunction
Official title: A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial to Evaluate the Safety and Efficacy of POM Wonderful Pomegranate Extract Capsules In Male Subjects With Moderate to Severe Erectile Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Erectile Dysfunction
Keywords: ED
POMx
Pomegranate
Erectile dysfunction
Lead sponsor: POM Wonderful LLC
Sponsor class: INDUSTRY
Collaborators: name: Target Health Inc.
First posted: 2010-10-13
Enrollment: 120
Sex: MALE
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: POMx can be used as a treatment for erectile dysfunction.


Eligibility criteria: Inclusion Criteria:

* Male 21 to 70 years old
* Erectile Function domain score of 10-19 on the International Index of Erectile Function (IIEF)
* In a stable, monogamous relationship with a consenting female partner and willing to attempt vaginal sexual intercourse on at least one occasion per week on average during each study period
* History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration
* Treated previously with a PDE-5 inhibitor with a satisfactory response, as defined by the patient.
* Signed informed consent

Exclusion Criteria:

-The presence of any of the following excludes a subject from study enrollment: ED caused by untreated endocrine disease, i.e., hypopituitarism, hypothyroidism, hypogonadism

* A diagnosis of situational psychogenic ED
* Significant penile pathology, including but not limited to curvature, fibrosis, sexually transmitted disease, and penile implant
* Clinically significant hepatic, renal, neurological disease, diabetes mellitus, spinal cord injury, significant coronary heart disease, significant neurological disease or hepatitis B and/or C
* History of prostate cancer or prostate surgery other than a transurethral resection of the prostate
* History of alcoholism within the previous 2 years
* Current consumer of three or more units of alcohol per day (1 unit is equivalent to 1 glass of wine, 1 pint of beer, or 1 shot of hard liquor)
* Taking ED therapy (prescription medications, over-the-counter medications, herbal preparations or medical devices) after the screening visit
* Participation in another study with an investigational drug or device during the 30 days prior to study entry
* Has a condition interfering with his ability to provide informed consent or comply with study instructions

Primary outcomes:
measure: Effects on ED
timeFrame: Basedline to end of study
Secondary outcomes:
measure: Effect on ED
timeFrame: baseline to end of study
Other outcomes:
Locations:
city: Huntsville
country: United States
facility: Medical Affiliated Research Center
state: Alabama
Study officials:
affiliation: Medical Affiliated Research Center, Inc.
name: James McMurray, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04917406: Effect of Iontophoresis vs. Ultrasound and Iontophoresis in Plantar Fasciitis". Plantar Fasciitis"
Official title: Randomized Clinical Trial: Comparison in the Treatment of Plantar Fasciitis by Iontophoresis Versus Ultrasound.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Iontophoresis
Ultrasound Therapy; Complications
Fasciitis, Plantar
Pain, Acute
Lead sponsor: University of Seville
Sponsor class: OTHER
First posted: 2021-06-08
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Plantar fasciitis is inflammation of plantar fascia.The main symptom of plantar fasciitis manifests itself as localized pain in the inner area of the foot and increases in intensity after long periods of standing or resting. Its etiology is multifactorial and risk factors include overweight, female gender, physical exercise (impact sports), biomechanical imbalances of the foot and possible dysfunction of the functional twin-ankle-plantar system.Generally speaking, conservative measures are recommended as initial treatment for plantar fasciitis, and in situations where these are ineffective, corticosteroids are sometimes administered. At the local level, the route of administration can be by infiltration or iontophoresis.Iontophoresis consists of administering a drug through the skin by applying an electric current locally. This technique can be considered as a safe and effective method within the SLTF (Transcutaneous Drug Delivery Systems). It consists of introducing ions through the skin by means of electricity using a direct current, with an electrode carrying a positive charge (anode) and a negative charge (cathode). Its administration is produced thanks to the repulsive force to carry the compound through the skin by means of galvanic current.

This study aims to assess whether treatment with iontophoresis in subjects with plantar fasciitis can show a more positive evolution in pain after a 6-week treatment period (treatment frequency: 1 time per week) versus ultrasound (3 times per week) for 6 weeks.


Eligibility criteria: Inclusion Criteria:

* plantar fasciitis
* fascia thickness (greater or equal to 4mm).

Exclusion Criteria:

* skin lesion
* sensory neuropathy
* current use of plantar supports
* taking pharmacological treatment (15 days) or previous infiltrations (6 months)
* previous surgery or fractures of the lower limb
* pregnancy
* allergy to the applied drugs.

Primary outcomes:
measure: Fasciitis pain
timeFrame: Baseline
measure: Health status
timeFrame: Baseline
measure: Plantar fascia thickness in mm
timeFrame: Baseline
Secondary outcomes:
measure: Patient Global Impression of Improvement PGI-I questionnaire
timeFrame: 1 month
Other outcomes:
Locations:
city: Sevilla
country: Spain
facility: Universidad de Sevilla
Study officials:
References:
Clinical trial NCT02112006: Comparing Two Injection Sites of Local Anesthetic for Hand Surgery
Official title: A Comparison Of Distal Peripheral Nerve Blockade Versus Traditional Proximal Approaches For Hand Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hand Injury
Wrist Injury
Finger Injury
Keywords: hand surgery
wrist surgery
finger surgery
anesthesia
regional anesthesia
postoperative pain
Lead sponsor: Ochsner Health System
Sponsor class: OTHER
First posted: 2014-04-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare two different injection sites for local anesthesia in patients having hand surgery. The hypothesis is that subjects receiving injections around the three nerves of the forearm will provide faster pain control and greater patient satisfaction than patients having one injection closer to the shoulder.


Eligibility criteria: Inclusion Criteria:

* Patients ≥ 18 years of age undergoing unilateral hand, wrist, or finger surgery
* Ability to understand and provide informed consent
* American Society of Anesthesiologists (ASA) status I-III

Exclusion Criteria:

* Patient refusal or inability to provide informed consent
* True allergy, not sensitivity, to any of the following substances: Local Anesthetics, Midazolam, Fentanyl, Hydromorphone, Propofol
* Pregnancy
* Severe hepatic impairment
* Evidence of infection at or near the proposed needle insertion site
* Any sensorimotor deficit of the ipsilateral upper extremity, whether acute or chronic, as determined by the PI and designee
* Pulmonary disease of any kind that is uncontrolled or severe in nature
* Chronic pain patients, defined as someone diagnosed with chronic pain or a chronic pain condition, under the care of a chronic pain physician, or taking oral/intravenous narcotics consistently for 30 days prior to surgery

Primary outcomes:
measure: success of block
timeFrame: up to 30 minutes after injection
Secondary outcomes:
measure: pain scores
timeFrame: up to 10 days after surgery
Other outcomes:
measure: time to complete injection
timeFrame: up to 30 minutes
Locations:
city: New Orleans
country: United States
facility: Ochsner Clinic Foundation
state: Louisiana
Study officials:
affiliation: Ochsner Health System
name: Jose Soberon, MD
role: PRINCIPAL_INVESTIGATOR
References: